State of Wyoming Has $258,000 Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)

State of Wyoming grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 40.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 39,772 shares of the company’s stock after acquiring an additional 11,394 shares during the period. State of Wyoming’s holdings in Cytek Biosciences were worth $258,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CTKB. Sterling Capital Management LLC raised its stake in shares of Cytek Biosciences by 799.8% in the 4th quarter. Sterling Capital Management LLC now owns 3,887 shares of the company’s stock valued at $25,000 after buying an additional 3,455 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Cytek Biosciences in the 4th quarter valued at $25,000. PNC Financial Services Group Inc. raised its stake in shares of Cytek Biosciences by 111.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,850 shares of the company’s stock valued at $57,000 after buying an additional 4,665 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Cytek Biosciences in the 4th quarter valued at $71,000. Finally, Cibc World Markets Corp acquired a new position in shares of Cytek Biosciences in the 4th quarter valued at $74,000. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Stock Down 1.2%

Shares of Cytek Biosciences stock opened at $2.42 on Friday. The stock has a market capitalization of $306.51 million, a P/E ratio of -30.25 and a beta of 1.42. The company has a 50-day simple moving average of $3.57 and a 200 day simple moving average of $5.09. Cytek Biosciences, Inc. has a 12-month low of $2.37 and a 12-month high of $7.63.

Cytek Biosciences (NASDAQ:CTKB) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. The company had revenue of $41.46 million for the quarter, compared to the consensus estimate of $43.18 million. On average, equities analysts anticipate that Cytek Biosciences, Inc. will post -0.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CTKB shares. Piper Sandler dropped their target price on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. TD Cowen cut shares of Cytek Biosciences from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research report on Friday, May 9th. Stephens reiterated an “overweight” rating and set a $6.00 target price on shares of Cytek Biosciences in a research report on Wednesday, March 19th. Finally, The Goldman Sachs Group dropped their target price on shares of Cytek Biosciences from $3.50 to $3.00 and set a “sell” rating for the company in a research report on Monday, May 12th.

Cytek Biosciences Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.